DIABESITY COMPANIES
Below is a list of companies working in the field of obesity and/or type 2 diabesity, either directly or through strategic collaborations. If you would like to add your company to this list, please send us an email at contactus@diabesitydigest.com.
| Company | Location | Ticker | Focus |
| 7TM Pharma www.7tm.com | Hørsholm, Denmark | Private | 7TM Pharma is a biotech company focusing on discovery and development of new drugs targeting 7TM receptors. 7TM Pharma's primary therapeutic area is metabolic diseases, including obesity, diabetes and cardiovascular diseases. |
| Abbott www.abbott.com | Chicago, Illinois | NYSE:ABT | A global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. |
| Action Pharma A/S www.actionpharma.com | Holte, Denmark | Private | Action Pharma is dedicated to the discovery and development of novel drugs that can significantly improve the therapy of inadequately treated cardiovascular diseases. The core therapeutic focus of our company is obesity, Type II diabetes / metabolic syndrome, inflammatory diseases, organ protection in severe cardiovascular diseases such as myocardial infarction, and post-surgical organ dysfunction. |
| ActivX Biosciences, Inc. - ACQUIRED by Kyorin www.activx.com | San Diego, California | Private | ActivX uses its unique technology to identify target and off-target activities of drug candidates in the protein kinase and protease families with an initial focus on the areas of hematology, oncology, metabolic and inflammatory diseases. ACQUIRED by Kyorin December, 2004. |
| Addex Pharmaceuticals www.addexpharma.com | Geneva, Switerland | Private | Addex Pharmaceuticals discovers and develops allosteric modulators for human health. Allosteric modulators are a different kind of orally available small molecule therapeutic agent, which we believe will offer patients better results than classical drugs. |
| AdipoGenix, Inc. - ACQUIRED by OSI Pharmceuticals www.osip.com | Boston, Massachusetts | Private | AdipoGenix is a biopharmaceutical company developing pharmaceuticals that target human fat tissue to treat obesity and its co-morbidities, including diabetes and cardiovascular disease. ACQUIRED by OSI Pharmaceuticals in 2007. |
| Aeterna Zentaris Inc. www.aeternazentaris.com | Quebec City, Canada | TSX:AEZ and Nasdaq: AEZS | Aeterna Zentaris Inc. is a global biopharmaceutical company focused on endrocrine therapy and oncology, with proven expertise in drug discovery, development and commercialization. |
| Ajinomoto Group www.ajinomoto.com | Tokyo, Japan | TSE:2802 | We aim to be a global corporation, which contributes to the general well-being of all people in the world, through our business domains of food and food-related products, amino acid-based fine chemicals and pharmaceuticals. |
| Akesis Pharmaceuticals, Inc. www.akesis.com | La Jolla, California | OTCBB:AKES | Akesis Pharmaceuticals is an emerging metabolic disease company with a unique, patent-protected product that utilizes the insulin enhancing activity of vanadium, a naturally occurring micro-nutrient. In January 2009, Akesis announced its intention to file for bankruptcy petition under Chapter 7 of the U.S. Bankrupcy Code based on the discontinuation of its sole clinical development program AKP-020. |
| Alantos Pharmaceuticals - ACQUIRED by Amgen www.amgen.com | Cambridge, Massachusetts | Private | Alantos Pharmaceuticals is a chemistry-driven biopharmaceutical company with a broad proprietary pipeline of small molecule drugs focused in the area of type II diabetes and Osteoarthritis/inflammation. ACQUIRED by Amgen in July 2007. |
| Alinea Pharmaceuticals | Cambridge, Massachusetts | Private | Alinea Pharmaceuticals is dedicated to developing and commercializing pharmaceuticals for the treatment of diabetes and related metabolic disorders. |
| Alizé Pharma SAS www.alz-pharma.com | Ecully, France | Private | Alizé Pharma SAS is a biopharmaceutical company specialized in the development of innovative therapeutics for the treatment of metabolic diseases. |
| Alizyme Plc www.alizyme.com | Cambridge, UK | LSE:AZM | Alizyme has a late stage, diversified portfolio of competitive products for the treatment of obesity and type 2 diabetes, ulcerative colitis and mucositis. |
| Alkermes, Inc. www.alkermes.com | Cambridge, Massachusetts | Nasdaq: ALKS | Alkermes, Inc., a biotechnology company committed to developing innovative medicines to improve patients' lives, manufactures RISPERDAL(R) CONSTA(R) for schizophrenia and developed and manufactures VIVITROL(R) for alcohol dependence. Alkermes' robust pipeline includes extended-release injectable, pulmonary and oral products for the treatment of prevalent, chronic diseases, such as central nervous system disorders, addiction and diabetes. |
| Ambrx Inc. www.ambrx.com | LaJolla, California | Private | Ambrx Pharmaceuticals, a leader in the field of protein optimization, is a biopharmaceutical company developing "best in class" protein and antibody drugs based on a breakthrough involving the site-specific incorporation of novel amino acids into proteins. Ambrx is currently focusing on the areas of metabolic diseases, endocrinology, and disorders of the central nervous system. |
| Amgen, Inc. www.amgen.com | Thousand Oaks, California | Nasdaq:AMGN | Amgen discovers, develops, manufactures and delivers innovative human therapeutics. |
| Amylin Pharmaceuticals www.amylin.com | San Diego, California | Nasdaq:AMLN | Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin's research and development activities leverage the company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. |
| Arena Pharmaceuticals www.arenapharm.com | San Diego, California | Nasdaq:ARNA | Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. |
| Areta Therapeutics www.aretatherpeutics.com | Hayward, California | Private | Arete Therapeutics is a privately-held biotechnology company dedicated to the discovery and development of novel first-in-class drugs to treat diabetes, as well as inflammatory and cardiovascular diseases. It is the world’s leading company focused on inhibition of s-EH (soluble epoxide hydrolase), an essential enzyme in the arachidonic acid metabolism pathway that has been implicated in a broad range of diseases including type II diabetes, obesity and hypertension. |
| Arexis AB - ACQUIRED by BioVitrum www.biovitrum.com | Molndal, Sweden | Private | Arexis AB develops pharmaceuticals for the treatment of metabolic and inflammatory diseases. ACQUIRED by Biovitrum in August 2005. |
| Arisaph Pharmaceuticals www.arisaph.com | Boston, Massachusetts | Private | Arisaph is an emerging drug design and discovery biopharmaceutical company with active programs to develop differentiated therapies for diabetes, cancer and cardiovascular disease. |
| Array BioPharma Inc. www.arraybiopharma.com | Boulder, Colorado | Nasdaq:ARRAY | Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, inflammatory and metabolic diseases. Our proprietary drug development pipeline includes clinical candidates that are designed to regulate therapeutically important target proteins and are aimed at significant unmet medical needs. |
| Astellas Pharma Inc. www.astellas.com | Japan | TSE:4503 | Astellas Pharma Inc. is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. |
| AstraZeneca www.astrazeneca.com | London, UK | LSE, NYSE and OMX:AZN | AstraZeneca is a major international healthcare business engaged in research, development, manufacturing and marketing of prescription pharmaceuticals and supplier for healthcare services. |
| AtheroGenics, Inc. www.atherogenics.com | Alpharetta, Georgia | Nasdaq:AGIX (delisted) | AtheroGenics is a pharmaceutical company focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, including diabetes and coronary artery disease (atherosclerosis). In October 2008, AtheroGenics filed for CHAPTER 11 BANKRUPTCY and was delisted from Nasdaq. |
| Athersys, Inc. www.athersys.com | Cleveland, Ohio | Nasdaq:ATHX | Athersys is a clinical stage biopharmaceutical company with a growing pipeline of highly differentiated, potential best in class therapeutics designed to treat significant and life-threatening diseases. The Company's lead programs are in the areas of obesity, cardiovascular disease (myocardial infarction), and bone marrow transplant support. |
| Bayer AG (Bayer HealthCare) www.bayerhealth.com | Leverkusen, Germany | FSE:BAYG | Bayer HealthCare, a subsidiary of Bayer AG, is one of the world's leading, innovative companies in the health care and medical products industry. |
| Bellus Health Inc. (formerly Neurochem) www.bellushealth.com | Laval, Canada | TSX:BLU | Bellus Health (formerly Neurochem) is a global health company focused on the development and commercialization of products to provide innovative health solutions to address critical unmet needs. |
| Betagenon AB www.betagenon.com | Stockholm, Sweden | Private | Betagenon is an early stage biotechnology company founded in 2001. Its goal is to become one of the leading companies in the discovery and early stage development of novel, safe and effective therapies for treatment of obesity-related disorders including type 2 diabetes, fatty liver, disorders linked to hyperinsulinemia, and various forms of cancer. |
| Biocompatibles International plc www.biocompatibles.com | Farnham, UK | LSE:BII | Biocompatibles is a leading medical technology company in the field of drug device combination products, operating through three businesses. The International Division conducts the marketing of Biocompatibles' approved Bead products, which are sold to hospitals by our distribution partners, including AngioDynamics Inc and Terumo Corporation. The Drug Delivery and CellMed businesses are engaged in new product development and licensing. |
| Biodel www.biodel.com | Danbury, Connecticut | Nasdaq:BIOD | Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for endocrine disorders, such as diabetes and osteoporosis. Biodel's product candidates are developed by using VIAdel(TM) technology, which reformulates existing FDA-approved peptide drugs. |
| Biorexis Pharmaceutical Corp. - ACQUIRED by Pfizer www.pfizer.com | King of Prussia, Pennsylvania | Private | BioRexis uses the abundant serum protein transferrin as a scaffold for developing improved versions of peptides, proteins and antibody-like molecules. ACQUIRED by Pfizer in February 2007. |
| Biotech Holdings www.biotechltd.com | Vancouver, Canada | TSX.V:BIO | Biotech has developed an important new anti-diabetic medication, which has been trademarked as "Sucanon" and "Diab II". Biotech is now focused on the distribution and marketing of this medication. |
| BioVitrum AB www.biovitrum.com | Stockholm, Sweden | OMX:BVT | Biovitrum is a pharmaceutical company with operations in Sweden and in the UK. The company markets a range of specialist pharmaceuticals primarily in the Nordic countries. |
| Boehringer Ingelheim GmbH www.boehringer-ingelheim.com | Ingelheim, Germany | Private | The Boehringer Ingelheim Group is one of the world's 20 leading pharmaceutical companies. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine. |
| Bristol-Myers Squibb Co. www.bms.com | New York, New York | NYSE:BMY | Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to extend and enhance human life. |
| Cambridge Biotechnology Ltd (CBT) www.camb-biotech.com | Cambridge, UK | Private | Cambridge Biotechnology Ltd (CBT) is a wholly owned subsidiary of Biovitrum AB. CBT specialises in the discovery and development of high value potential "First-in-Class" therapeutics in the fields of pain/inflammation and obesity using two core platforms: the targeting of drug action to low pH tissues (apHinity), and peptide-mimetic chemistry. |
| CombinatoRx www.combinatorx.com | Cambridge, Massachusetts | Nasdaq:CRXX | CombinatoRx, Incorporated is pioneering the new field of synergistic combination pharmaceuticals and has a broad product portfolio in Phase 2 clinical development. |
| Conjuchem Biotechnologies Inc. www.conjuchem.com | Montreal, Canada | TSX:CJC | Conjuchem Biotechnologies Inc. is dedicated to the discovery of novel therapeutics with an initial focus on diabetes. |
| Daiichi-Sankyo www.daiichisankyo.com | Japan | TSE:4568 | A central focus of Daiichi Sankyo's research and development is cardiometabolic diseases, including therapies for thrombosis, dyslipidemia, hypertension, diabetes, and acute coronary syndromes. |
| Dainippon Sumitomo Pharma Co.,Ltd. www.ds-pharma.co.jp | Osaka, Japan | TSE:4506 | In October 2005, Dainippon Sumitomo Pharma Co., Ltd. was formed through the merger of Dainippon Pharmaceutical Co., Ltd. and Sumitomo Pharmaceuticals Co., Ltd. to create a company that can reinforce the earnings base of the domestic pharmaceutical business, strengthen the quality and increase the capacity of R&D operations based on steady cash flows, increase the speed of product development and expand overseas businesses over the long term. |
| DARA BioSciences Inc. (formerly Point Therapeutics Inc.) www.darabiosciences.com | Raleigh, North Carolina | Nasdaq:DARA | DARA is a development-stage pharmaceutical company that acquires and develops promising drug candidates. DARA focuses its therapeutic development efforts on small molecules from late preclinical development through phase 2 clinical trials. DARA has a portfolio of drug candidates for neuropathic pain, type 2 diabetes, and psoriasis. |
| DeveloGen www.develogen.com | Goettingen, Germany | Private | DeveloGen is a biopharmaceutical company engaged in the discovery and development of novel therapeutics for the treatment of metabolic and endocrine disorders. |
| Devgen www.devgen.com | Ghent, Belgium | Euronext:DEVG | Devgen's biopharmaceutical division develops a new class of preclinical drug candidates, based on novel therapeutic concepts, for treatment of a range of inflammatory and metabolic disease (diabetes, obesity) and arrhythmia. |
| Diabetica Limited www.diabetica.co.uk | Coleraine, Northern Ireland | Private | Diabetica (Diabetica Limited) focuses on innovative research in diabetes therapeutics. |
| Diakine Therapeutics www.diakine.com | Charlottesville, Virginia | Private | DiaKine Therapeutics, Inc. is a development-stage company commercializing novel immune modulators such as Lisofylline (LSF) and related oral compounds into therapies for diabetes and related complications. These drugs have the potential to stop the progression of diabetes and reverse damage already caused by the disease. |
| Diamedica www.diamedica.com | Winnipeg, Canada | TSX:DMA | DiaMedica is developing novel treatments for various stages of type 2 diabetes. |
| Diamyd Medical AB www.diamyd.com | Stockholm, Sweden | OMX:DIAM B and OTCQX:DMYDY | Diamyd Medical's vision is that there is a cure to be found for autoimmune diabetes. The Company's mission is to contribute in the global effort to find this cure and to eliminate complications from the disease. |
| DiObex www.diobex.com | San Diego, California | Private | DiObex, Inc., is a privately held biotechnology company developing novel products for diabetes and metabolic diseases. In April 2009, venture backers of the Company laid off all its employees and were looking to sell its assets. |
| DOV Pharmaceuticals, Inc. www.dovpharm.com | Somerset, New Jersey | OTCBB:DOVP | We are a biopharmaceutical company focused on the development of novel product candidates for disorders of the central nervous system, or CNS. |
| Dr. Reddy's Laboratories Ltd. www.drreddys.com | India | NYSE:RDY | Dr. Reddy's conducts research in the areas of diabetes, cardiovascular, anti-infectives, inflammation and cancer. The Indian based company produces finished dosage forms, active pharmaceutical ingredients and biotechnology products which are marketed globally, with focus on India, US, Europe and Russia. |
| Eli Lilly and Company, Inc. www.lilly.com | Indianapolis, Indiana | NYSE:LLY | Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own world-wide laboratories and from collaborations with eminent scientific organizations. |
| Elixir Pharmaceuticals www.elixirpharm.com | Cambridge, Massechusetts | Private | Elixir is a pharmaceutical company focused on the discovery, development and commercialization of novel pharmaceuticals for the treatment of metabolic diseases such as diabetes and obesity. |
| Emishpere Technologies, Inc. www.emisphere.com | Cedar Knolls, New Jersey | Nasdaq: EMIS | Emisphere is charting new frontiers in drug delivery. The Company's core business strategy is to use its proprietary Eligen® Technology to develop novel oral forms of injectable drugs or poorly absorbed compounds. |
| Epix Pharmaceuticals www.epixpharma.com | Lexington, Massachusetts | Nasdaq:EPIX | EPIX Pharmaceuticals is a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform. The company has a pipeline of internally-discovered drug candidates currently in clinical development to treat diseases of the central nervous system and lung conditions. |
| FASgen www.fasgen.com | Baltimore, Maryland | Private | At FASgen, our mission is to develop and commercialize small molecule therapeutics and diagnostics using fatty acid biosynthesis targets. |
| FivePrime Therapeutics www.fiveprime.com | San Francisco, California | Private | Five Prime Therapeutics, Inc. is a pre-clinical stage biotech company discovering innovative protein and antibody therapeutics using its world-class discovery platform. We are using this platform to comprehensively screen secreted proteins and receptors using novel cell-based and in vivo screening systems. We are building a strong pipeline that currently includes product candidates in development for cancer and diabetes and multiple leads in our oncology, metabolic disease and immunology programs. |
| Forest Laboratories www.frx.com | New York, New York | NYSE: FRX | Forest Laboratories is a U.S.-based pharmaceutical company with a long track record of building partnerships and developing and marketing products that make a positive difference in people's lives. In addition to its well-established franchises in therapeutic areas of the central nervous and cardiovascular systems, Forest's current pipeline includes product candidates in all stages of development and across a wide range of therapeutic areas. |
| Galapagos NV www.glpg.com | Mechelen, Belgium | Euronext:GLPG | Galapagos entered into a multi-year global strategic alliance with Merck & Co., Inc. to develop potential new therapies in obesity and diabetes. Galapagos has discovered new drug targets (human proteins that are starting points for the development of novel drugs) using human primary cells relevant for rheumatoid arthritis, osteoarthritis and osteoporosis. Galapagos applies these targets to find small molecules that change the activity of these proteins and thereby can influence the course of the disease. |
| Galenea Corp. www.galenea.com | Cambridge, Massachusetts | Private | Galenea, an emerging biopharmaceutical company, is dedicated to enhancing and saving lives through the discovery of novel therapies for CNS diseases. Galenea has a program to develop a selective 5-HT2C agonist for the treatment of obesity. |
| Genaera www.genaera.com | Plymouth Meeting, Pennsylvania | Nasdaq:GENR | Genaera Corporation is focused on advancing the science and treatment of metabolic diseases. |
| Generex Biotechnology www.generex.com | Toronto, Canada | Nasdaq:GNBT | Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). |
| Genfit Corp. www.genfit.com | Lille, France | Alternext: ALGFT | Genfit is an innovative biopharmaceutical company, enabling and developing 'first' or 'best to market' medicines for the prevention and treatment of cardiometabolic disease, the leading cause of mortality in the world. |
| Genmedica Therapeutics www.genmedica.com | Barcelona, Spain | Private | Genmedica Therapeutics is a development stage biotechnology company focusing on type 2 diabetes. They have three first in class programs. |
| Glaxo Smithkline Plc www.gsk.com | Middlesex , UK | LSE & NYSE:GSK | GlaxoSmithKline is one of the world's leading research-based pharmaceutical and healthcare companies. |
| Glenmark Pharmaceuticals Limited www.glenmarkpharma.com | Mumbai, India | BSE and NSE:GLENMARK | Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global, integrated pharmaceutical company. The Company is a leader in India in the discovery of new molecules and is focused in the areas of inflammation [Asthma/COPD, etc.], dermatology and metabolic disorders [Diabetes, Obesity, etc.]. |
| Glucox Biotech www.glucox.se | Stockholm, Sweden | Private | The primary goal of Glucox Biotech is to develop a clinically applicable therapeutic drug for treatment of type 2 diabetes and insulin resistance. |
| Hollis-Eden Pharmaceuticals, Inc. www.holliseden.com | San Diego, California | Nasdaq:HEPH | Hollis-Eden Pharmaceuticals, Inc. is a world leader in the development of a proprietary class of adrenal steroid hormones as novel pharmaceuticals for human health. |
| Human Genome Sciences www.hgsi.com | Rockville, Maryland | Nasdaq: HGSI | The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs. The HGS clinical development pipeline includes novel drugs to treat hepatitis C, lupus, inhalation anthrax, cancer and other immune-mediated diseases. |
| Incyte Corporation www.incyte.com | Wilmington, Delaware | Nasdaq:INCY | Incyte Corporation is a drug discovery and development company focused on developing proprietary small molecule drugs to treat serious unmet medical needs. Incyte's pipeline includes multiple compounds in Phase I and Phase II development for oncology, inflammation and diabetes. |
| Innodia Inc. - ACQUIRED by Bellus Health www.innodia-inc.com | Laval, Canada | Private | Innodia is a privately held biopharmaceutical company engaged in developing and bringing to the market novel oral drugs for the treatment of obesity and diabetes. ACQUIRED by Bellus Health in July 2008. |
| Institute for Diabetes Discovery idd-diabetes.com | Branford, Connecticut | Private | The Institute for Diabetes Discovery, LLC, (IDD) is the largest privately-held biopharmaceutical company in the United States dedicated to the research and discovery of novel drugs and therapeutics for diabetes. Founded in 1995 in Branford, Connecticut, IDD is the flagship institute under the umbrella of the Institutes for Pharmaceutical Discovery, LLC. |
| Intarcia Therapeutics, Inc. www.intarcia.com | Hayward, California | Private | Intarcia Therapeutics, Inc. is a biopharmaceutical company developing therapies to ensure enhanced treatment outcome by optimizing patient adherence and improving the convenience and tolerability of drug therapies. |
| Intekrin Therapeutics www.intekrin.com | Los Altos, California | Private | InteKrin Therapeutics is a clinical-stage, privately held BioPharma company focused on developing and commercializing breakthrough therapeutics for neuroendocrine, metabolic, and immune disorders. |
| Ipsen www.ipsen.com | Paris, France | Euronext:IPN | Ipsen is an innovation driven international specialty pharmaceutical group. Its development strategy is based on a complementary combination of specialised products, which are growth drivers, in the Group's targeted therapeutic areas (oncology, endocrinology and neuromuscular disorders) and primary care products, which help finance its Research and development activities. |
| Isis Pharmaceuticals www.isispharm.com | Carlsbad, California | Nasdaq:ISIS | Isis Pharmaceuticals, Inc. is a leading drug discovery and development company, focused exclusively on the therapeutic target, RNA. |
| J&J (Ortho-McNeil Pharmaceuticals, Inc.) www.jnj.com | New Brunswick, New Jersey | NYSE:JNJ | Caring for the world, one person at a time ... inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. |
| Joslin Diabetes Center www.joslin.org | Boston, Massachusetts | Private | Affiliated with Harvard Medical School, Joslin Diabetes Center is the world's largest diabetes research center, diabetes clinic and provider of diabetes education. |
| Jurilab Ltd. www.jurilab.com | Helsinki, Finland | Private | Jurilab is a leader in the discovery of proprietary genes and genetic markers associated with the root cause of common diseases. These markers enable developments in diagnostic, therapeutic and preventive healthcare. Our initial focus has been on metabolic and cardiovascular diseases. |
| Kalypsys, Inc. www.kalypsys.com | San Diego, California | Private | Kalypsys is a biopharmaceutical company with clinical stage pharmaceutical products. Central to our pipeline expansion is epiK a proprietary and highly automated small molecule drug discovery platform. |
| Karo Bio www.karobio.com | Huddinge, Sweden | OMX:KARO | Karo Bio is a drug discovery and development company specializing in nuclear receptors for the development of novel pharmaceuticals. |
| Kissei Pharmaceuticals Co., Ltd. www.kissei.co.jp | Nagano, Japan | TSE:4547 | Kissei Pharmaceutical Co., Ltd., headquartered in Matsumoto, Nagano prefecture, founded in 1946, is a research and development oriented pharmaceutical company that manufacture and sells brand pharmaceutical products. Kissei is primarily focused on two important fields of new drug research: genitourinary system and metabolism & endocrinology. |
| Kowa Pharmaceuticals www.kowa.co.jp | Japan | Private | Kowa's R&D focuses on ethical drugs for so-called "Lifestyle related diseases" (such as hyperlipidemia, atherosclerosis, diabetes), "Immune and Allergic diseases" and "Indication Extension,applying transdermal and/or ophthalmic formulations". |
| Kyorin Pharmaceutical Co., Ltd. www.kyorin-pharm.co.jp | Tokyo, Japan | TSE:4560 | Our drug discovery operations are centered on three therapeutic fields: infectious, immunological/allergic and metabolic diseases. |
| Lexicon Pharmaceuticals www.lexicon-genetics.com | Teh Woodlands, Texas | Nasdaq:LXRX | Lexicon Pharmaceuticals is a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease. Using its proprietary gene knockout technology, Lexicon has discovered more than 100 promising drug targets, and created a unique, growing clinical pipeline in the fields of cardiology, gastroenterology,immunology, metabolism, and ophthalmology. |
| LG LifeSciences Ltd. www.lgls.com | Seoul, Korean | KRX:068870 | LG Life Sciences, Ltd., an LG affiliate, is the leading pharmaceutical company based in committed to promoting health and well-being of patients. Its key therapeutic areas include metabolic and cardiovascular diseases as well as infectious and liver diseases. |
| Ligand Pharmaceuticals Inc. www.ligand.com | San Diego, California | Nasdaq:LGND | Ligand Pharmaceuticals Incorporated (Ligand) is an early-stage biotech company that focuses on discovering and developing new drugs that address critical unmet medical needs in the areas of thrombocytopenia, anemia, cancer, hormone-related diseases, osteoporosis and inflammatory diseases. |
| Manhattan Pharmaceuticals www.manhattanpharma.com | New York, New York | OTCBB:MHAN | Manhattan Pharmaceuticals, Inc. is a pharmaceutical company that acquires and develops novel, high value drug candidates primarily for the treatment of dermatologic and immune disorders. |
| MannKind Corporation www.mannkindcorp.com | Valencia, Clalifornia | Nasdaq:MNKD | MannKind is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. |
| MDRNA, Inc. (formerly Nastech Pharma Co.) www.mdrnainc.com | Bothell, Washington | Nasdaq: MRNA | MDRNA is developing RNAi-based product candidates for the treatment of cancer, metabolic disorders, inflammation, and viral infections. |
| Merck & Co.,Inc. www.merck.com | Whitehouse Station, New Jersey | NYSE:MRK | Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. |
| Merck KGaA www.merck.de | Damstadt, Germany | FWB:MRK | Merck is a global pharmaceutical and chemical company. |
| Metabasis Therapeutics, Inc. www.mbasis.com | La Jolla, California | Nasdaq:MBRX | Metabasis is a biopharmaceutical company focused on the discovery, development and commercialization of novel drugs by applying its proprietary technologies, scientific expertise and unique capabilities for targeting the liver and liver pathways. |
| Metabolex Inc. www.metabolex.com | Hayward, California | Private | Metabolex is a privately-held biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, with an emphasis on type 2 diabetes. |
| Metabolic Pharmaceuticals Limited www.metabolic.com.au | Melbourne, Australia | ASX:MBP, Nasdaq OTC:MBLPY | Metabolic Pharmaceuticals' focus is to take drug candidates through research, formal preclinical and clinical development. |
| MicroIslet Inc. www.microislet.com | San Diego, California | OTCBB:MIIS | MicroIslet is a biotechnology company engaged in the research, development, and commercialization of patented technologies in the field of cell therapy for patients with insulin-dependent diabetes. According to the November 12, 2008, San Diego Business Journal, MicroIslet filed for Chapter 11 bankruptcy protection and hopes to emerge as a private company. |
| Mitsubishi-Tanabe Pharma www.mt-pharma.co.jp | Osaka, Japan | TSE:4508 | Manufacture and sale of pharmaceuticals, centered on ethical pharmaceuticals. |
| Nektar Therapeutics www.nektar.com | San Carlos, California | Nasdaq:NKTR | Nektar Therapeutics is a biopharmaceutical company that develops and enables differentiated therapeutics with its industry-leading PEGylation and pulmonary drug development platforms. |
| Neuren Pharmaceuticals www.neurenpharma.com | New Zealand | ASX:NEU | A novel and dynamic biopharmaceutical company developing human therapies for neuroprotection, metabolic disease and growth-related disorders. |
| Neurogen Corporation www.neurogen.com | Branford, Connecticut | Nasdaq:NRGN | Neurogen is a small-molecule drug development company focusing on the treatment of psychiatric and neurological disorders, including insomnia, Parkinson's disease, restless legs syndrome (RLS), anxiety, and pain. |
| NeuroSearch A/S www.neurosearch.com | Ballerup, Denmark | OMX:NEUR | NeuroSearch is dedicated to the discovery, development and commercialisation of novel and unique medicines to satisfy unmet medical needs. Our core business is to treat diseases of the central nervous system and selected somatic diseases primarily through the modulation of ion channels or monoamine transporters. |
| Novartis Pharma AG www.novartis.com | Basel, Switzerland | SWX:NOVZn and NYSE:NVS | Novartis AG provides healthcare solutions that address the evolving needs of patients and societies. |
| Novo Nordisk AS www.novonordisk.com | Bagsvaerd, Denmark | NYSE:NVO and LSE:NVOB | Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. |
| Novocell, Inc. www.novocell.com | San Diego, California | Private | Novocell, Inc. is a stem cell engineering company dedicated to creating, delivering and commercializing cell and drug therapies for diabetes and other chronic diseases. Novocell has three primary technologies: stem cell engineering, cell encapsulation and drug discovery. |
| Noxxon Pharma AG www.noxxon.net | Berlin, Germany | Private | Based on one of best protected technology platforms in the industry, Noxxon Pharma AG develops biostable aptamers, novel substances using mirror image nucleic acids. |
| Obecure ltd. www.obecure.com | Ramat Gan, Israel | Private | Obecure is a specialty pharmaceutical company dedicated to the development of novel therapeutic approaches for weight management. |
| ObeTherapy Biotechnology www.obetherapy.com | Evry, France | Private | ObeTherapy is a French biotech company dedicated to the discovery of new targets and the development of new drugs for obesity, hypercholesterolemia and type II diabetes. |
| Ono Pharmaceuticals Co.,Ltd. www.ono.co.jp | Osaka, Japan | TSE:4528 | Production, purchase and sale of pharmaceuticals and diagnostic reagents focusing primarily on prescription pharmaceuticals. |
| Oramed Pharmaceuticals www.oramed.com | Jerusalem, Israel | OTCBB:ORMP | Oramed is a company focused on the commercial development of proprietary oral therapies. Currently, Oramed's main focus is the treatment of diabetes via an oral insulin capsule, which has the potential to help millions of diabetics worldwide. |
| Orexigen Therapeutics, Inc. www.orexigen.com | San Diego, California | Nasdaq:OREX | Orexigen is a biopharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system disorders, including obesity. |
| OSI Pharmaceuticals, Inc. www.osip.com | Melville, New York | Nasdaq:OSIP | OSI Pharmaceuticals is committed to "shaping medicine and changing lives" by discovering, developing and commercializing high-quality and novel pharmaceutical products designed to extend life and/or improve the quality of life for patients with cancer and diabetes/obesity. |
| Osiris Therapeutics www.osiristx.com | Baltimore, Maryland | Nasdaq:OSIR | Osiris Therapeutics, Inc. is a leading stem cell therapeutic company focused on developing products to treat medical conditions in the inflammatory, orthopedic and cardiovascular areas. |
| Peptimmune, Inc. www.peptimmune.com | Boston, Massachusetts | Private | Peptimmune is a clinical stage biotechnology company developing peptide and peptide-copolymer therapeutics for the treatment of CNS and Autoimmune disorders. |
| Perlegen Sciences, Inc. www.perlegen.com | Mountain View, California | Private | Perlegen's mission is to discover and commercialize genetic variations that can make a difference to patients and physicians. |
| Pfizer Inc. www.pfizer.com | New York, New York | NYSE:PFE and LSE:PFZ | Founded in 1849, Pfizer is the world's largest research-based pharmaceutical company taking new approaches to better health. |
| Phenomix Corporation www.phenomixcorp.com | San Diego, California | Private | Phenomix is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. |
| Phosphagenics Limited www.phosphagenics.com | Melbourne, Australia | ASX:POH | Phosphagenics is a globally driven biotechnology company focused on the discovery of new and cost effective ways to enhance the bioavailability, activity, safety and delivery of proven pharmaceutical and nutraceutical products. |
| Physiogenix www.physiogenix.com | Labege, France | Private | Physiogenex is a world leading CRO specializing in metabolic and cardiovascular diseases and in predictive functional validation. |
| Plexxikon www.plexxikon.com | Berkeley, California | Private | Plexxikon is a leader in the discovery and development of novel, small molecule pharmaceuticals. The company has utilized its proprietary discovery platform to successfully develop a portfolio of clinical and preclinical stage programs in a number of therapeutic areas, including metabolic disease, oncology, inflammation, CNS and cardiovascular disease. |
| PPD, Inc. www.ppdi.com | Wilmington, North Carolina | Nasdaq:PPDI | PPD is a leading global contract research organization providing discovery, development and post-approval services as well as compound partnering programs. PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help its clients and partners maximize returns on their R&D investments and accelerate the delivery of safe and effective therapeutics to patients. |
| Probiodrug AG www.probiodrug.de | Halle/Saale, Germany | Private | Probiodrug is a biopharmaceutical company focused on the development of innovative small molecule drugs for the treatment of neuronal, inflammatory, and autoimmune diseases. The Company has pioneered the field of DP4-inhibition for the treatment of type-2 diabetes. |
| Protemix Corp. Ltd. www.protemix.co.nz | San Diego, CA and Auckland, New Zealand | Private | Protemix is a privately held biopharmaceutical company that discovers, develops and commercializes novel drug therapies for the prevention and treatment of cardiovascular disease, diabetes and other metabolic disorders, and their complications. |
| Regeneron www.regeneron.com | Tarrytown, New York | Nasdaq:REGN | Regeneron is a biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions. |
| Rheoscience AS www.rheoscience.com | Roedovre, Denmark | Private | Some of the world's leading pharmaceutical and biotech companies depend on Rheoscience for their obesity and diabetes research. |
| Roche www.roche.com | Basel, Switzerland | SWX:ROG | Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. |
| Sanofi-Aventis www.sanofi-aventis.com | Paris, France | Euronext:SAN and NYSE:SNY | Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. |
| Santhera Pharmaceuticals AG www.santhera.com | Liestal, Switzerland | SWX:SANN | Santhera is a Swiss specialty pharmaceutical company focusing on the discovery, development and marketing of small molecule products for the treatment of severe neuromuscular diseases, an area of high unmet medical needs. |
| Sanwa Kagaku Kenkyusho Co., Ltd. www.skk-net.com | Nagoya, Japan | Private | SKK allocates its resources primarily in the area of diabetic care, and our activities range from the R&D through marketing of ethical pharmaceuticals, diagnostic products that include the patient-friendly and easy-to-use self-monitoring system for blood glucose and medical nutrition products. |
| Senexis www.senexis.com | Cambridge, UK | Private | Senexis is developing novel small molecule inhibitors of amyloid aggregation as potential therapeutic agents to inhibit and reverse the pathogenic process of protein misfolding, amyloid-related toxicity and inflammation. |
| Servier (Les Laboratoires) www.servier.com | Paris, France | Private | The leading French independent pharmaceutical company. |
| Shionogi & Co., Ltd. www.shionogi.co.jp | Osaka, Japan | TSE:4507 | Shionogi & Co., Ltd. is a major research-driven Japanese pharmaceutical manufacturer. The company's primary businesses are research and development, manufacturing, marketing, and import and export sales of pharmaceuticals and diagnostics. |
| Sirna Therapeutics - ACQUIRED by Merck www.sirna.com | San Francisco, California | Private | Sirna Therapeutics is at the forefront of the effort to create RNAi- based therapies and leverage the vast potential of this technology to ultimately treat patients. ACQUIRED by Merck Oct. 2006 |
| Sirona Biochem Corp. www.sironabiochem.com | Vancouver, Canada | TSX-V: HRD.P | Sirona Biochem Corp. currently known as High Rider Capital Inc. (HRC) is a Capital Pool Company (CPC) and is in the final stages of completing a "Qualifying Transaction" through acquisition of a highly valued asset. HRC has intentions of becoming a biotech company dedicated to the discovery and development of innovative biochemical molecules. The current focus is on treatments for Type II Diabetes and Obesity. |
| Sirtris Pharmaceuticals Inc. - ACQUIRED by GlaxoSmithKline www.sirtrispharma.com | Cambridge, Massachusetts | Private | Sirtris is developing small molecule drugs that target the sirtuins, a recently discovered family of seven enzymes associated with the aging process. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. ACQUIRED by GlaxoSmithKline in June 2008. Sirtris continues to operate as an automonous drug discovery unit part of GSK's Drug Discovery organisation. |
| Solvay S.A. www.solvay.com | Brussels, Belgium | Private | Solvay Pharmaceuticals operates in two main therapeutic areas, in which it undertakes a full range of Research and Development activities: - Cardiometabolics (including the fenofibrate franchise) - Neuroscience |
| Surface Logix, Inc. www.surfacelogix.com | Brighton, Massachusetts | Private | Surface Logix is a drug development company which uses its expertise in biophysical chemistry to create new small molecule drugs with significantly improved pharmacokinetic (PK) and pharmacodynamic (PD) properties compared with class leaders. |
| Syrxx, Inc. - ACQUIRED by Takeda www.syrxx.com | San Diego, California | Private | Syrrx Inc focuses on drug targets that have been validated in human clinical trials and directs its efforts toward therapeutics to treat metabolic diseases, cancer, and inflammation. ACQUIRED by Takeda Pharmaceuticals in February 2005 and renamed Takeda San Diego, Inc. |
| Taisho Pharmaceutical Co.,Ltd. www.taisho.co.jp | Tokyo, Japan | TSE:4535 | Focused on core areas of activities in CNS, diabetes, immunology/allergy and infectious diseases. |
| Takeda Pharmaceutical Company Ltd. www.takeda.com | Osaka, Japan | TSE:4502 | We strive toward better health for individuals and progress in medicine by developing superior pharmaceutical products. |
| TFChem S.A.R.L. www.tfchemistry.com | Rouen, France | Private | TFChem is a Drug Discovery company. TFChem licenses its technology of fluorinated carbohydrate mimics: GlycoMim®, and products in development to pharmaceutical comapnies in the therapeutic areas of cancer, pain and inflammatory disorders, diabetes... |
| The Institute for Diabetes Discovery LLC www.idd-diabetes.com | Branford, Connecticut | Private | The IDD vision is to be the premier research company in the United States dedicated to the discovery of novel drugs and therapeutics for diabetes, its complications, obesity, and related disorders |
| Thiakis Limited - ACQUIRED by Wyeth www.thiakis.com | London, United Kingdom | Private | Thiakis was founded in 2004 by Professor Steve Bloom and Dr John Burt to focus on the development of peptide hormones that regulate appetite, based on the research of Professor Bloom's group at Imperial College London. ACQUIRED by Wyeth in December 2008. |
| TolerRx Inc. www.tolerrx.com | Cambridge, Massachusetts | Private | Tolerx is a biopharmaceutical company engaged in the discovery and development of novel therapies for immune-mediated diseases. |
| Transition Therapeutics Inc. www.transitiontherapeutics.com | Toronto, Canada | TSX:TTH and Nasdaq:TTHI | Transition Therapeutics Inc. is a biopharmaceutical company with a proprietary state-of-the art drug discovery engine and extensive drug development program exploring novel therapeutics in multiple disease indications. |
| Transtech Pharma www.ttpharma.com | High Point, North Carolina | Private | Transtech is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of human therapeutics to fill unmet medical needs. The company has a pipeline of small molecule clinical and pre-clinical drug candidates for the treatment of a wide range of human diseases including central nervous system disorders, cardiovascular disorders, type I/II diabetes, obesity, and cancer. |
| Vernalis plc www.vernalis.com | Cambridge, United Kingdom | LSE: VER | Vernalis is a research and development based bio-pharmaceutical company with one marketed product, frovatriptan, six product candidates in clinical trials and a research capability based on structure-based drug discovery technologies. |
| Verva Pharmaceuticals Ltd. vervapharma.com | Geelong, Australia | Private | Verva Pharmaceuticals Ltd. is an exciting, clinical-stage pharmaceutical company developing innovative therapies to treat metabolic diseases. Verva's research efforts are focused on the treatment of type 2 diabetes and the prevention and reversal of obesity and related complications. |
| Vitae Pharmaceuticals, Inc. www.vitaepharma.com | Fort Washington, Pennsylvania | Private | Vitae Pharmaceuticals is an emerging pharmaceutical company dedicated to being a leader in rapidly discovering, developing and commercializing innovative, high value small molecule medicines, focusing on known biologic targets with significant unmet medic |
| Vivus, Inc. www.vivus.com | Mountain View, California | Nasdaq:VVUS | Vivus, Inc. is a pharmaceutical company dedicated to the development and commercialization of next-generation therapeutic products addressing obesity and sexual health. |
| Wellstat Therapeutics Corporation www.wellstat.com | Gaithersburg, Maryland | Private | Wellstat Therapeutics™ Corporation is dedicated to the discovery, development and commercialization of innovative therapeutics that expand the frontier of modern medicine. Wellstat Therapeutics Corporation is committed to improving the lives of patients with chronic and life-threatening diseases. Wellstat Therapeutics’ focus is in the following fields:oncology and hematology, metabolic diseases and neurology. |
| Wyeth Pharmaceuticals - ACQUIRED by Pfizer www.wyeth.com | Madison, New Jersey | NYSE:WYE | Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. In January 2009, Pfizer announced that it was acquiring Wyeth. |
| Xenon Pharmaceuticals Inc. www.xenon-pharma.com | Vancouver, Canada | Private | Xenon is a privately owned, clinical genetics-based drug discovery and development company engaged in developing small molecule therapies focusing in pain, lipid modification for treating diabetes/obesity, and other diseases, as well as therapies for treating anemia and diseases of iron overload. |
| Xoma Ltd. www.xoma.com | Berkeley, California | Nasdaq:XOMA | XOMA discovers, develops and manufactures therapeutic antibody and other agents designed to treat inflammatory, autoimmune, infectious and cancerous diseases. The company's proprietary product pipeline includes XOMA 052, an anti-IL-1 beta antibody, and XOMA 3AB, a biodefense anti-botulism antibody candidate. |
| Zafgen Inc. www.zafgen.com | Cambridge, Massachusetts | Private | Zafgen is the first biopharmaceutical company dedicated to developing novel obesity therapeutics based on vascular targeting in adipose tissue (fat). Our groundbreaking approach directly targets adipose vasculature to shrink fat cells and help the body sustain a lean, healthy state. |
| Zealand Pharma A/S www.zp.dk | Golstrup, Denmark | Private | Zealand Pharma is a biopharmaceutical company dedicated to the discovery and development of innovative peptide-based drugs. The products target diseases and symptoms of significant unmet clinical need and commercial potential. |